Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

NCT05183035 is registered in ClinicalTrials.gov with PedAL BCU, LLC as lead sponsor.

NCT NCT05183035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05183035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML
Lead sponsor
PedAL BCU, LLC
Phase
Phase 3
Overall status
Recruiting
Start date
October 1, 2022
Completion date
April 30, 2031
Enrollment
130 (estimated)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia